Table 4.
Univariable Cox proportional hazard analysis for overall death in patients with epithelioid MPM in no neoadjuvant chemotherapy(no-NAC) and neoadjuvant chemotherapy (NAC) cohorts.
| Cohorts | No-NAC | NAC | ||||||
|---|---|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | P | HR | 95% CI | P | ||
| Age (per 1 year increase) | 1.01 | 0.99, 1.02 | 0.4 | 1.01 | 0.99, 1.04 | 0.3 | ||
| Male (vs. female) | 1.32 | 0.92, 1.90 | 0.13 | 1.86 | 1.02, 3.42 | 0.045 | ||
| Smoking (vs. no smoking) | 1.35 | 0.86, 2.11 | 0.2 | 0.95 | 0.52, 1.75 | 0.9 | ||
| Asbestos (vs. no asbestos) | 1.12 | 0.73, 1.71 | 0.6 | 1.38 | 0.77, 2.47 | 0.3 | ||
| Procedure (vs. EPP) | PD | 0.88 | 0.63, 1.23 | 0.5 | 1.08 | 0.60, 1.94 | 0.8 | |
| Other | 1.00 | 0.46, 2.18 | 1.0 | 1.14 | 0.35, 3.76 | 0.8 | ||
| R2 (vs. R1) | 1.16 | 0.73, 1.85 | 0.5 | 1.15 | 0.48, 2.75 | 0.7 | ||
| Postoperative chemotherapy (vs. no chemotherapy) | 0.60 | 0.40, 0.89 | 0.012 | |||||
| p-Stage III/IV (vs. I/II) | 2.20 | 1.52, 3.18 | <0.001 | 1.14 | 0.65, 1.98 | 0.6 | ||
| T category (vs. T1) | T2 | 2.32 | 1.14, 4.72 | 0.020 | 0.32 | 0.11, 0.98 | 0.045 | |
| T3 | 3.12 | 1.53, 6.39 | 0.002 | 0.54 | 0.18, 1.60 | 0.3 | ||
| T4 | 2.59 | 1.01, 6.62 | 0.047 | 0.53 | 0.13, 2.15 | 0.4 | ||
| N category (vs. N0) | N1 | 2.59 | 1.45, 4.60 | 0.001 | 0.66 | 0.09, 4.81 | 0.7 | |
| N2 | 1.38 | 0.94, 2.02 | 0.10 | 0.98 | 0.47, 2.05 | 1.0 | ||
| Pleomorphic positive (vs. negative) | 1.79 | 1.13, 2.82 | 0.013 | 1.57 | 0.78, 3.16 | 0.2 | ||
| Lymphatic invasion positive (vs. negative) | 1.53 | 1.10, 2.11 | 0.011 | 1.55 | 0.88, 2.74 | 0.13 | ||
| Vascular invasion positive (vs. negative) | 1.97 | 1.34, 2.89 | 0.001 | 1.20 | 0.65, 2.22 | 0.6 | ||
| CD3 high (vs. low) | 1.08 | 0.78, 1.50 | 0.6 | 0.90 | 0.52, 1.54 | 0.7 | ||
| CD4 high (vs. low) | 0.75 | 0.54, 1.04 | 0.083 | 1.04 | 0.60, 1.78 | 0.9 | ||
| CD8 high (vs. low) | 0.73 | 0.52, 1.02 | 0.062 | 0.86 | 0.50, 1.48 | 0.6 | ||
| CD20 high (vs. low) | 0.71 | 0.51, 0.98 | 0.039 | 0.47 | 0.26, 0.84 | 0.011 | ||
| FoxP3 high (vs. low) | 0.91 | 0.66, 1.26 | 0.6 | 1.07 | 0.61, 1.88 | 0.8 | ||
| CD68 high (vs. low) | 1.28 | 0.92, 1.77 | 0.14 | 0.75 | 0.43, 1.31 | 0.3 | ||
| CD163 high (vs. low) | 1.06 | 0.76, 1.47 | 0.7 | 1.67 | 0.92, 3.02 | 0.092 | ||
| Ki-67 high (vs. low) | 2.24 | 1.58, 3.18 | <0.001 | 1.03 | 0.59, 1.78 | 0.9 | ||
| gC1qR high (vs. low) | 0.69 | 0.50, 0.96 | 0.029 | 0.53 | 0.30, 0.91 | 0.022 | ||
| CD4-gC1qR combination* | CD4 | gC1qR | ||||||
| High | High | Ref | ||||||
| Low | Low | 1.70 | 1.06, 2.75 | 0.029 | ||||
| Low | High | 2.17 | 1.36, 3.45 | 0.001 | ||||
| High | Low | 2.26 | 1.43, 3.55 | <0.001 | ||||
| Ki-67-gC1qR combination* | Ki67 | gC1qR | ||||||
| Low | High | Ref | ||||||
| Low | Low | 2.41 | 1.49, 3.90 | <0.001 | ||||
| High | Low | 3.08 | 1.85, 5.14 | <0.001 | ||||
| High | High | 4.04 | 2.42, 6.74 | <0.001 | ||||
Data are number (%) or median (25 and 75 percentiles).
*
Combination based on significant interactions between 2 variables in no NAC cohort. MPM, malignant pleural mesothelioma; NAC, neoadjuvant chemotherapy; EPP, extrapleural pneumonectomy; PD, pleurectomy/decortication; gC1qR, globular heads of the C1q receptor; Foxp3, forkhead box P3. Bold values indicate significant p-value.